Welcome to our dedicated page for Monte Rosa Therapeutics news (Ticker: GLUE), a resource for investors and traders seeking the latest updates and insights on Monte Rosa Therapeutics stock.
Monte Rosa Therapeutics develops molecular glue degrader medicines for serious diseases using its QuEEN discovery engine, which combines AI-guided chemistry, chemical libraries, structural biology and proteomics. The company’s news centers on clinical and preclinical updates for programs including MRT-8102, a NEK7-directed degrader for inflammatory disease biology; MRT-2359, a GSPT1-directed degrader studied in metastatic castration-resistant prostate cancer; and MRT-6160, a VAV1-directed degrader for immune-mediated diseases.
Recurring developments also include oncology discovery work such as cyclin E1-directed and CDK2-directed degrader programs, clinical supply and pharmaceutical collaboration activity, quarterly financial results, equity awards, capital resources and public-company governance updates.
Monte Rosa Therapeutics (Nasdaq: GLUE) granted inducement equity awards to three new non-executive employees under its 2026 Inducement Plan, in line with Nasdaq Listing Rule 5635(c)(4).
Awards include options on 18,025 shares at $24.02 and 3,900 restricted stock units with multi-year vesting.
Monte Rosa Therapeutics (Nasdaq: GLUE) granted inducement equity awards to four new non-executive employees under its 2026 Inducement Plan, in line with Nasdaq Listing Rule 5635(c)(4).
The awards include options for 20,050 shares at $19.67 and 4,400 restricted stock units, with multi-year, service-based vesting schedules.
Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotech focused on molecular glue degrader medicines, will join two investor events. Management will participate in fireside chats at the TD Cowen 7th Annual Oncology Innovation Summit on May 27, 2026, and the Jefferies Global Healthcare Conference on June 4, 2026.
Live webcasts and 30-day archives will be available in the Events & Presentations section of the company’s investor relations website.
Monte Rosa Therapeutics (Nasdaq: GLUE) reported Q1 2026 results and program updates on May 7, 2026. Key clinical highlights include MRT-8102 interim data showing CRP -85% and 94% of subjects below 2 mg/L, MRT-2359 tumor activity in mCRPC, and preclinical CCNE1 program with IND planned in H2 2026. Financially, cash and marketable securities were $671.2M, expected to support operations into 2029.
Monte Rosa Therapeutics (Nasdaq: GLUE) granted inducement equity awards to four newly hired non-executive employees under its 2026 Inducement Plan on May 1, 2026. The awards include non-qualified stock options for 38,925 shares at an $18.80 exercise price and 8,550 restricted stock units, with standard time-based vesting.
Monte Rosa Therapeutics (Nasdaq: GLUE) will present preclinical data on its CCNE1-directed molecular glue degrader, MRT-55811, at AACR on April 21, 2026. Data show potent, selective CCNE1 degradation, tumor regressions in CCNE1-amplified ovarian, breast, and gastric models, and superior selectivity versus CDK2 inhibitors.
The company expects to submit an IND for the program later in 2026.
Monte Rosa Therapeutics (Nasdaq: GLUE) reported Q4 and full‑year 2025 results and program updates on March 17, 2026. Key clinical highlights include MRT-8102 showing an 85% CRP reduction after four weeks and 94% of participants reaching CRP <2 mg/L. The company closed a $345M follow‑on financing and reports cash and marketable securities of $382.1M as of Dec 31, 2025, supporting operations into 2029.
Other items: favorable safety/tolerability data for MRT-8102; MRT-2359 showed 100% PSA responses in a 5/5 AR‑mutant mCRPC subset; planned Phase 2 starts in 2026–2027; Novartis and Roche collaborations provide milestone upside.
Monte Rosa Therapeutics (Nasdaq: GLUE) announced a supply agreement with Johnson & Johnson to support a planned Phase 2 study of MRT-2359 plus apalutamide for metastatic castration-resistant prostate cancer (mCRPC) with androgen receptor (AR) mutations.
The signal-confirming Phase 2 is expected to start in Q3 2026, will enroll up to 25 patients, and will assess PSA response, RECIST response, duration of response, PFS, rPFS, and safety. Prior positive Phase 1/2 combination data were presented on Feb 26, 2026.
Monte Rosa Therapeutics (Nasdaq: GLUE) reported updated Phase 1/2 data for MRT-2359 plus enzalutamide in heavily pretreated mCRPC patients, presented at ASCO GU on Feb 26, 2026. Key findings: 100% PSA response (5/5) and 100% RECIST disease control in AR-mutant patients; overall RECIST DCR 67% (10/15); 10 of 15 showed tumor size reductions. Safety was manageable with mainly Grade 1–2 AEs and no discontinuations for AEs. Company plans a signal-confirming Phase 2 in AR-mutant mCRPC starting Q3 2026 to assess PSA, RECIST, rPFS and safety.
Monte Rosa Therapeutics (Nasdaq: GLUE) announced management will present at three investor conferences in March 2026: TD Cowen (Mar 2), Barclays (Mar 10) and Jefferies Biotech on the Beach (Mar 11).
Presenters include CEO Markus Warmuth and CMO Filip Janku. Webcasts will be available via the company’s Events & Presentations page and archived for 30 days.